Skip to content
Parakho

Advanced Enzyme Technologies Ltd

NSE ADVENZYMESBSE 540025advancedenzymes.com

Q1 FY27, unaudited

Revenue
₹115.86 Cr
Profit after tax
₹22.35 Cr

As filed with the exchange, standalone basis.

Statement of profit and loss

Figures in ₹ crore, reproduced from the results data files the company filed with NSE under Regulation 33 of the SEBI (LODR) Regulations. Nothing is restated, adjusted or estimated.

Statement of profit and loss, standalone basis
₹ croreQ1 FY27vs a year agoFY26
Revenue from operations115.86−7.33%452.77
Other income2.29−95.75%63.39
Total income118.14−33.95%516.15
Employee benefit expense17.69+9.17%64.73
Finance costs0.04−30.19%0.21
Depreciation & amortisation2.92−0.27%12.08
Total expenses88.40−9.31%354.62
Profit before tax29.74−63.46%157.67
Tax expense7.40−0.27%25.87
Profit after tax22.35−69.79%131.81
Total comprehensive income22.35−69.79%132.65
Earnings per share
Earnings per share, basic₹2.00₹11.78
Earnings per share, diluted₹1.99₹11.76

Q1 FY27 — unaudited, from the company’s filing with NSE. Source

Q1 FY26, the year-ago base — unaudited, from the company’s filing with NSE. Source

FY26 — from the company’s filing with NSE. Source

Q1 FY27 results for every company Parakho holds

Earnings call

Q1 FY27

Advanced Enzyme Technologies reported Q1 FY27 revenue of INR 1,898 million, up 2% YoY but down 7% sequentially, with management attributing the softness to an incremental sales reversal of INR 100 million related to revenue recognition timing. EBITDA declined 10% YoY to INR 510 million with margin at 27%, which management said was due to lower top-line realization, elevated power and fuel costs, and a temporary shift in sales mix. The company also announced a buyback of INR 697 million and the acquisition of the remaining 4.28% stake in JC Biotech, making it a wholly-owned subsidiary.

Generated by AI from the filed transcript; every statement on the full page carries its verbatim quote.

Read the full summary

Earlier calls: Q4 FY26 · All quarters

Filings

12 shown · 94 published by the exchange

BSE corporate announcements, classified by Parakho. The exchange’s own category is kept alongside our classification so a reclassification never rewrites history.

Industry

Healthcare › Biotechnology

Classification as published by BSE.

Companies also in Biotechnology, in alphabetical order

All 6 companies in Biotechnology

Page generated from filings held to 12 Oct 2026.